Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Daphne, Tsoi"'
Autor:
Anna K Nowak, Robert U Newton, Travis Cruickshank, Prue Cormie, Georgia K B Halkett, Daphne Tsoi, Daniel A Galvão
Publikováno v:
Neuro-Oncology Practice. 10:261-270
Background While therapeutically effective, chemoradiotherapy treatment for high-grade glioma (glioblastoma) is often accompanied by side effects. Exercise has been demonstrated to alleviate the adverse effects of such treatments in other cancers. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5886ad37a5d9756dd2ace29bb513fe3
https://doi.org/10.1093/nop/npad006
https://doi.org/10.1093/nop/npad006
Autor:
Nicolas H. Hart, Daniel A. Galvão, Christobel Saunders, Dennis R. Taaffe, Kynan T. Feeney, Nigel A. Spry, Daphne Tsoi, Hilary Martin, Raphael Chee, Tim Clay, Andrew D. Redfern, Robert U. Newton
Publikováno v:
Trials, Vol 19, Iss 1, Pp 1-15 (2018)
Abstract Background Skeletal metastases present a major challenge for clinicians, representing an advanced and typically incurable stage of cancer. Bone is also the most common location for metastatic breast carcinoma, with skeletal lesions identifie
Externí odkaz:
https://doaj.org/article/351c8f89ea7c4b82b0a1e3e79b981ca9
Autor:
Hui Jun Chih, Kerry Cheong, Elizabeth Blackely, Christopher Lomma, Daphne Tsoi, Mitchell Chipman, Andrew Redfern, Arlene Chan, Natasha Woodward
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 18:201-208
Purpose Review of utilization and efficacy of eribulin in Australian metastatic breast cancer (MBC) patients. Methods Retrospective review of consecutive MBC patients treated with eribulin in tertiary Australian BC centers. Key inclusion criteria inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfdbb313efe0b73b1bc723489ccc4359
https://doi.org/10.1111/ajco.13576
https://doi.org/10.1111/ajco.13576
Autor:
Maximilian Hochmair, A. Poltoratskiy, Michael Schumacher, Rafal Dziadziuszko, Silvia Novello, Konstantin Laktionov, Inna Egorova, Maria Rita Migliorino, Filippo de Marinis, W. Tang, Daphne Tsoi, Simona Rizzato, Gyula Ostoros, Antonio Passaro, L. Clementi, Agnieszka Cseh, Guzel Z Mukhametshina, Giulio Metro, Dariusz M. Kowalski, Maya Gottfried
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 152
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable treatment option for patients with epidermal growth factor receptor mutation-positive (EGFRm +) non-small cell lung cancer (NSCLC). However, such studies often excl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c1c210914756da50d9c8f367b45ec1d
https://pubmed.ncbi.nlm.nih.gov/33387727
https://pubmed.ncbi.nlm.nih.gov/33387727
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 12:5-15
Aim: Treatment with pertuzumab-trastuzumab-taxane combinations has become the international standard of care for patients with HER2-positive metastatic breast cancer. In this paper we discuss the practicalities of treating patients with this combinat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4c3927ccfd000a6b6a44b8dd11c50a5
https://doi.org/10.1111/ajco.12500
https://doi.org/10.1111/ajco.12500
Autor:
S Della Fiorentina, Nicole McCarthy, R De Boer, J Rutovitz, Daphne Tsoi, Ross R Jennens, Janine M. Lombard, S S Foo, BE Kiely, M F Cronk, Jacquie Chirgwin, L Chin-Lenn, T M Hughes, Yoland Antill, Gavin Marx, G B Mann, Stuart White, A Gorelik, Eva Segelov
Publikováno v:
Cancer Research. 76:P5-15
Background: An Australian industry-funded decision impact study demonstrated that Oncotype Dx (ODX) changed treatment recommendations (TR) in 24% of hormone receptor+/HER2- patients. ODX is available in Australia, but is self-funded by patients (∼U
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0fabf0ea30a07fcfa4454ee07a1a734
https://doi.org/10.1158/1538-7445.sabcs15-p5-15-02
https://doi.org/10.1158/1538-7445.sabcs15-p5-15-02
Autor:
Richard De Boer, Michael R. Green, Sally Baron-Hay, Kerrie Clarke, Sheau Wen Lok, Peter Gibbs, Elgene Lim, Frances M. Boyle, Robert Blum, Katharine Cuff, Ali Tafreshi, Belinda Yeo, Louise M. Nott, Kelly Mok, Daphne Tsoi, Michelle Nottage, Nick Murray, Laeeq Malik
Publikováno v:
Cancer Research. 80:OT2-02
Background: The combination of CDK 4/6 inhibition and endocrine therapy has emerged as the new first line standard of care treatment for patients with hormone receptor (HR) +ve metastatic breast cancer (MBC)1. Ribociclib plus letrozole has been shown
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4bf1fd368b94386dc9f480bde06cf8b
https://doi.org/10.1158/1538-7445.sabcs19-ot2-02-01
https://doi.org/10.1158/1538-7445.sabcs19-ot2-02-01
Autor:
Dennis R. Taaffe, Raphael Chee, Nicolas H. Hart, Robert U. Newton, Daphne Tsoi, Timothy D. Clay, Nigel Spry, Kynan T. Feeney, H. Martin, Andrew Redfern, Christobel Saunders, Daniel A. Galvão
Publikováno v:
Trials
Trials, Vol 19, Iss 1, Pp 1-15 (2018)
Trials, Vol 19, Iss 1, Pp 1-15 (2018)
Background Skeletal metastases present a major challenge for clinicians, representing an advanced and typically incurable stage of cancer. Bone is also the most common location for metastatic breast carcinoma, with skeletal lesions identified in over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eee58447198fc844d5696cd73096343
https://pubmed.ncbi.nlm.nih.gov/30572928
https://pubmed.ncbi.nlm.nih.gov/30572928
Autor:
Kathleen I. Pritchard, Aliya Khan, Sunil Verma, Daphne Tsoi, Tom Ferguson, Anna K. Nowak, Angela M. Cheung
Publikováno v:
The Cochrane Library
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the efficacy and safety of bisphosphonates for the prevention of bone loss caused by cancer treatment in women with early breast cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d5990091731386bd52adc8adb17dc92
https://europepmc.org/articles/PMC6491074/
https://europepmc.org/articles/PMC6491074/
Publikováno v:
Integrative Cancer Therapies. 15:190-196
Background. Malignant brain tumors are unpredictable and incurable, with 5-year survival rates less than 30%. The poor prognosis combined with intensive treatment necessitates the inclusion of complementary and supportive therapies that optimize qual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::929bfa4f5a6594394b2584f30e4c8945
https://doi.org/10.1177/1534735415600068
https://doi.org/10.1177/1534735415600068